Use of flunarizine and method for controlling number of intercellular mitochondria
US-2024325381-A1 · Oct 3, 2024 · US
HCV entry factor, Occludin
US8940960B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8940960-B2 |
| Application number | US-200913122339-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 1, 2009 |
| Priority date | Oct 3, 2008 |
| Publication date | Jan 27, 2015 |
| Grant date | Jan 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A transgenic animal having integrated in the genome of the animal a human Occludin transgene and a human CD81 transgene wherein expression of the transgenes render the animal permissive for Hepatitis C Virus (HCV) entry and wherein said animal is selected from the group consisting of a mouse and a rat. 2. The transgenic animal of claim 1 , wherein said animal is a mouse.
Assignees
Inventors
Classifications
Physics · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- G01N33/5008Primary
Physics · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8940960B2 cover?
- The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mit…
- Who is the assignee on this patent?
- Ploss Alexander, Evans Matthew, Rice Charles, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5008. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).